Design and synthesis of dendrimeric tris(nonofluoro tert-butyl)-DOTA dual MRI agents using CuAAC reaction

Authors

• Suryakiran Navath Department of pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore 21201 USA

Abstract

Cancer therapeutics are designed to interfere with one or more events in cell propagation or survival. However, the healthy cells may also need to thrive and avoid apoptosis, anticancer agents can be toxic to such cells. To minimize these toxicities, approaches have been developed wherein the therapeutic agent is targeted to tumor cells through conjugation to a tumor-cell-specific small-molecule ligand, thus reducing delivery to normal cells and the associated collateral toxicity. This article describes the novel tris(nonofluoro tert-butyl)-DOTA derived drug imaging agents in the design of ligand-targeted drugs and ligand–drug conjugates and ligand–imaging-agent conjugates.